These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 15811958)
21. Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Sethi G; Ahn KS; Sung B; Aggarwal BB Mol Cancer Ther; 2008 Jun; 7(6):1604-14. PubMed ID: 18566231 [TBL] [Abstract][Full Text] [Related]
22. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. Takada Y; Aggarwal BB J Biol Chem; 2004 Feb; 279(6):4750-9. PubMed ID: 14630924 [TBL] [Abstract][Full Text] [Related]
23. Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Manna SK; Aggarwal RS; Sethi G; Aggarwal BB; Ramesh GT Clin Cancer Res; 2007 Apr; 13(7):2290-7. PubMed ID: 17404114 [TBL] [Abstract][Full Text] [Related]
27. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. Takada Y; Aggarwal BB J Immunol; 2003 Sep; 171(6):3278-86. PubMed ID: 12960358 [TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. Shishodia S; Koul D; Aggarwal BB J Immunol; 2004 Aug; 173(3):2011-22. PubMed ID: 15265936 [TBL] [Abstract][Full Text] [Related]
29. Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis. Kunnumakkara AB; Ichikawa H; Anand P; Mohankumar CJ; Hema PS; Nair MS; Aggarwal BB Mol Cancer Ther; 2008 Oct; 7(10):3306-17. PubMed ID: 18852134 [TBL] [Abstract][Full Text] [Related]
31. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. Takada Y; Ichikawa H; Badmaev V; Aggarwal BB J Immunol; 2006 Mar; 176(5):3127-40. PubMed ID: 16493072 [TBL] [Abstract][Full Text] [Related]
32. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. Majumdar S; Lamothe B; Aggarwal BB J Immunol; 2002 Mar; 168(6):2644-51. PubMed ID: 11884428 [TBL] [Abstract][Full Text] [Related]
33. Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression. Ichikawa H; Nair MS; Takada Y; Sheeja DB; Kumar MA; Oommen OV; Aggarwal BB Clin Cancer Res; 2006 Oct; 12(19):5910-8. PubMed ID: 17021000 [TBL] [Abstract][Full Text] [Related]
34. 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells. Yadav VR; Prasad S; Gupta SC; Sung B; Phatak SS; Zhang S; Aggarwal BB J Biol Chem; 2012 Jan; 287(1):245-256. PubMed ID: 22065587 [TBL] [Abstract][Full Text] [Related]
35. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Ichikawa H; Takada Y; Shishodia S; Jayaprakasam B; Nair MG; Aggarwal BB Mol Cancer Ther; 2006 Jun; 5(6):1434-45. PubMed ID: 16818501 [TBL] [Abstract][Full Text] [Related]